<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002855</url>
  </required_header>
  <id_info>
    <org_study_id>DM95-231</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-95231</secondary_id>
    <secondary_id>NCI-G96-1044</secondary_id>
    <secondary_id>CDR0000065105</secondary_id>
    <nct_id>NCT00002855</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer</brief_title>
  <official_title>A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining hormone therapy with chemotherapy and androgen
      suppression may kill more tumor cells. It is not yet known which treatment regimen is more
      effective for prostate cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone
      therapy versus androgen suppression alone as initial therapy in patients with prostate cancer
      that is metastatic or that cannot be removed surgically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the clinical benefit, as measured by time to progression and overall survival,
           of chemo/hormonal therapy compared to androgen ablation alone, when given as the initial
           systemic treatment in patients with acinar adenocarcinoma of the prostate that is not
           amenable to local therapy.

        -  Validate the clinical significance of PSA criteria for progression.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients are treated with medical or surgical castration followed by an
           anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.

        -  Arm II: Patients receive chemo/hormonal therapy for 3 eight week courses, followed by
           total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with
           doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks of rest.
           These patients are also maintained on hydrocortisone both during treatment and during
           rest.

      Patients in arm II have a long-term central venous access device inserted.

      PROJECTED ACCRUAL: A total of 368 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From baseline to post treatment (minimally 24+ weeks)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estramustine Phosphate Sodium</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Emcyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Eulexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilutamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Anandron</other_name>
    <other_name>Nilandron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Hydrocortisone</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>A-hydroCort</other_name>
    <other_name>Cortef</other_name>
    <other_name>Cortenema</other_name>
    <other_name>Cortifoam</other_name>
    <other_name>Hydrocortone</other_name>
    <other_name>Solu-Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Velban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <description>Surgical castration</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Castration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven acinar adenocarcinoma of the prostate

          -  Metastatic or locally advanced disease that either is not appropriately treated with
             surgery or radiation, or has recurred following previous &quot;definitive&quot; local therapy

          -  No CNS metastases

          -  No histologic subtypes, such as pure ductal or any component of small cell carcinoma

          -  Elevated PSA (at least 1.0 ng/mL in patients with prior prostatectomy or 4.0 ng/mL in
             those with prostate in place)

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  At least 3 years

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Conjugated bilirubin no greater than 0.8 mg/dL or total bilirubin no greater than 1.5
             mg/dL

          -  Transaminase no greater than 4 times upper limit of normal

        Renal:

          -  Creatinine clearance at least 40 mL/min

        Cardiovascular:

          -  No evidence of bifascicular block on EKG

          -  No evidence of active ischemia on EKG

          -  No prior history of transient ischemic attack

          -  No evidence of congestive heart failure

        Other:

          -  No active peptic ulcer disease

          -  No regular use of antacid or H2 blockers

          -  No known or predicted achlorhydria

          -  No concurrent use of terfenadine, astemizole, omeprazole, or cisapride

          -  No second malignancy unless curatively treated

          -  No history of deep venous thrombosis

          -  No history of pulmonary embolism

          -  No serious co-morbidity

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior cytotoxic systemic therapy

        Endocrine therapy:

          -  Prior androgen deprivation therapy allowed if given for no more than 6 months to
             downstage primary

          -  No androgen deprivation therapy within 1 year prior to study

        Radiotherapy:

          -  No prior cytotoxic systemic therapy (including systemic strontium-89 irradiation)

          -  Prior definitive radiotherapy to the prostate and/or one metastatic site allowed

          -  At least 8 weeks since radiotherapy to the pelvis

          -  At least 3 weeks since radiotherapy to a single metastatic site

        Surgery:

          -  Prior prostatectomy allowed

        Other:

          -  No concurrent anti-anginal therapy or aggressive anticoagulants
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall E. Millikan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <results_reference>
    <citation>Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20;26(36):5936-42. doi: 10.1200/JCO.2007.15.9830. Epub 2008 Nov 24.</citation>
    <PMID>19029421</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Estramustine</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

